As PDE4 inhibitors have been recently approved for clinical use in COPD (Rabe, 2011; Wedzicha et al., 2016) and psoriasis (Rich et al., 2016), our present results encourage further research to validate the use of these drugs in patients with CF. The gene discussed is PDE4A; the disease is cystic fibrosis.